Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis.

ABSTRACT:

Background

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been declared a global pandemic and urgent treatment and prevention strategies are needed. Nitazoxanide, an anthelmintic drug, has been shown to exhibit in vitro activity against SARS-CoV-2. The present study used physiologically based pharmacokinetic (PBPK) modelling to inform optimal doses of nitazoxanide capable of maintaining plasma and lung tizoxanide exposures above the reported SARS-CoV-2 EC₉₀ .

Methods

A whole-body PBPK model was validated against available pharmacokinetic data for healthy individuals receiving single and multiple doses between 500 and 4000 mg with and without food. The validated model was used to predict doses expected to maintain tizoxanide plasma and lung concen

SUBMITTER: Rajoli RKR 

PROVIDER: S-EPMC8056737 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature